Abstract
Calbindin (CB) is a calcium binding protein reported to protect dopaminergic neurons from degeneration. Although a direct link between CB content and differential vulnerability of dopaminergic neurons has long been accepted, factors other than CB have also been suggested, particularly those related to the dopamine transporter. Indeed, several studies have reported that CB levels are not causally related to the differential vulnerability of dopaminergic neurons against neurotoxins. Here we have used dual stains for tyrosine hydroxylase (TH) and CB in 3 control and 3 MPTP-treated monkeys to visualize dopaminergic neurons in the ventral tegmental area (VTA) and in the dorsal and ventral tiers of the substantia nigra pars compacta (SNcd and SNcv) co-expressing TH and CB. In control animals, the highest percentages of co-localization were found in VTA (58.2%), followed by neurons located in the SNcd (34.7%). As expected, SNcv neurons lacked CB expression. In MPTP-treated animals, the percentage of CB-ir/TH-ir neurons in the VTA was similar to control monkeys (62.1%), whereas most of the few surviving neurons in the SNcd were CB-ir/TH-ir (88.6%). Next, we have elucidated the presence of CB within identified nigrostriatal and nigroextrastriatal midbrain dopaminergic projection neurons. For this purpose, two control monkeys received one injection of Fluoro-Gold into the caudate nucleus and one injection of cholera toxin (CTB) into the postcommissural putamen, whereas two more monkeys were injected with CTB into the internal division of the globus pallidus (GPi). As expected, all the nigrocaudate- and nigroputamen-projecting neurons were TH-ir, although surprisingly, all of these nigrostriatal-projecting neurons were negative for CB. Furthermore, all the nigropallidal-projecting neurons co-expressed both TH and CB. In summary, although CB-ir dopaminergic neurons seem to be less prone to MPTP-induced degeneration, our data clearly demonstrated that these neurons are not giving rise to nigrostriatal projections and indeed CB-ir/TH-ir neurons only originate nigroextrastriatal projections.
Introduction
Parkinson’s disease (PD) is characterized by a progressive and selective loss of midbrain dopaminergic (DA) neurons. This cell loss follows a heterogeneous pattern as described in PD patients. The greatest loss of DA neurons is found in the substantia nigra pars compacta (SNc, group A9), whereas DA neurons in the ventral tegmental area (VTA, group A10) are known to be less vulnerable (German et al., ; Damier et al., ,; Lu et al., ). Within the SNc, neurons in the ventrolateral and caudal regions are more prone to degenerate than those in the rostromedial and dorsal region of the SNc. (German et al., , ; Lu et al., ).
Animal models for PD showed a similar pattern of midbrain DA neurons loss (German et al., , ; Varastet et al., 1994; Liang et al., ; Oiwa et al., ; Fitzpatrick et al., ). Systemic administration of MPTP to non-human primates induces a selective nigrostriatal degeneration mimicking the pattern of differential vulnerability of DA neurons observed in PD patients; the greatest loss being found in ventrolateral territories of the SNc (Schneider et al., ; Schneider and Dacko, ; Varastet et al., 1994).
It has been suggested that this selective vulnerability of midbrain DA neurons could be related with diverse differentiation routes during embryonic development (Smits et al., 2006; Smidt and Burbach, 2007), originating different DA phenotypes. Although the mechanism responsible for the preferential loss of DA neurons is still under discussion, a number of neuroprotective mechanisms have been suggested. Although several studies appointed the calcium-binding protein known as calbindin (CB; Gerfen et al., , ; Yamada et al., 1990; Ng et al., ; Yuan et al., 2013) as a putative neuroprotective agent, candidates other than CB such as the vesicular monoamine transporter (VMAT2; Liu et al., ; Harrington et al., ; Miller et al., ; Caudle et al., ; Afonso-Oramas et al., ) have also been suggested.
The fact that CB-immunopositive neurons in the SNc are relatively preserved in patients and animal models of PD (Yamada et al., 1990; Lavoie and Parent, ; Ito et al., ; Damier et al., ; Choi et al., ; Yuan et al., 2013), have led to the idea that CB could confer some neuroprotection to DA neurons against degeneration (Gerfen et al., , ; Yamada et al., 1990; Ng et al., ; Yuan et al., 2013). CB regulates the availability of calcium ions (Ca+2) within the cell, thus buffering the calcium overload and thereby protecting the cell against neurotoxicity (Reisner et al., ). In midbrain DA neurons the Ca+2 channels are opened much more time than in any other cell types (Wilson and Callaway, 2000), because they show an unusual physiological phenotype; they are autonomously active showing a pacemaking activity (Grace and Bunney, ). The need to maintain Ca+2 homeostasis includes the coordination of endoplasmatic reticulum pumps, the uptake of Ca+2 into mitochondria and lysosome function; these Ca+2 pathways interact with the mitochondrial function and oxidative stress both of which appears to be involved in the pathogenesis of PD (Schapira et al., ; Selvaraj et al., 2009, ; Surmeier et al., 2011; Davey and Bolaños, ). Bearing in mind all these data, the CB theory hypothesized that the resilience of CB immunoreactive DA neurons in the midbrain is due to the presence of calcium binding proteins; which effectively sequester Ca+2 without using ATP, so CB reduces vulnerability to mitochondrial toxins and seems to confer resistance to the PD-related neurotoxic agents (German et al., ; Ito et al., ; Damier et al., ; Hurley et al., ; Yuan et al., 2013).
Tract-tracing studies in the monkey showed that DA midbrain neurons also differ in their projection patterns (Haber and Fudge, ; Smith and Kieval, 2000), nigrostriatal and nigroextrastriatal projections (nigropallidal and the nigrosubthalamic) arise from different groups of midbrain DA neurons (Fallon and Moore, ; Lindvall and Björklund, ; Lavoie et al., ; Smith et al., 1989; Cossette et al., ; Hedreen, ; François et al., ; Jan et al., ; Smith and Kieval, 2000; Anaya-Martinez et al., ). The nigrostriatal projection arises from the SNc, VTA and retrorubral area (RRA): (1) the postcomissural putamen (sensorimotor striatum) is mainly targeted by DA cells located in the ventral tier of the SNc; (2) the limbic ventral striatum is innervated by DA neurons from the VTA and dorsal tier of the SNc; and (3) the caudate nucleus (associative striatum) is mainly innervated by DA neurons situated in the ventral tier of the SNc (Haber and Fudge, ; François et al., ; Smith and Kieval, 2000). The external and internal globus pallidus (GPi) as well as the subthalamic nucleus receive sparse collaterals from the nigrostriatal pathway but those nuclei also receive TH input from the nigroextrastriatal projections (Lavoie et al., ; Hassani et al., ; Cossette et al., ; Hedreen, ; François et al., ; Cragg et al., ). The nigropallidal projection is originated in the SNc and RRA (Jan et al., ), while the nigrosubthalamic projection arises from the SNc, VTA and RRA (Lavoie et al., ; François et al., ). The nigroextrastriatal projections also show a topographical organization similar to the one described in the striatum (François et al., ; Jan et al., ; Rommelfanger and Wichmann, ).
Different reports in MPTP-non-human primates have shown that the cells in the midbrain area that are able to resist chronic MPTP treatment are mostly DA neurons that express CB (CB-ir; Lavoie and Parent, ; German et al., ). The fact that the globus pallidus of MPTP-treated animals showed TH immunoreactive (TH-ir) sparing fibers (Varastet et al., 1994) suggests that the DA surviving neurons in the midbrain are involved in the nigroextrastriatal pathways instead of the nigrostriatal pathway (Parent et al., ; Varastet et al., 1994).
The purpose of the present study was to identify the DA midbrain neurons expressing CB in Macaca fascicularis, in control and MPTP-treated animals. Once the TH-ir neurons that also express CB-ir were identified in different midbrain areas, neuronal tracers were used to disclose whether these neuronal phenotypes were involved in the nigrostriatal and/or nigroextrastriatal pathways.
Material and methods
A total of ten naïve adult male Macaca fascicularis primates (body weight 3.8–4.5 kg) were used in this study. Animal handling was conducted in accordance with the European Council Directive 2010/63/UE, as well as in agreement with the Society for Neuroscience Policy on the Use of Animals in Neuroscience Research. The experimental design was approved by the Ethical Committee for Animal Testing of the University of Navarra. All animals were captive-bred and supplied by R.C. Hartelust (The Netherlands).
MPTP treatment
The dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; Sigma M0896) was administered intravenously to three macaques at a concentration of 0.3 mg/kg (injected weekly) until animals reached a stable parkinsonian syndrome. The severity of the MPTP-induced parkinsonism was evaluated using clinical rating scales (Kurlan et al., ) where the highest score was 29. The clinical features used in this scale included: facial expression (0–3), resting tremor (0–3), action or intention tremor (0–3), posture (0–2), gait (0–3), bradykinesia (0–3), balance/coordination (0–3), gross motor skills upper limb (0–3), gross motor skills lower limb (0–3), defense reaction (0–2). The MPTP-treated macaques reached a stable score between 19–23 points that was maintained over a period of 3 months of MPTP washout.
Stereotaxic surgery, perfusion and tissue processing
Surgical anesthesia was induced by intramuscular injection of ketamine (0.5 mg/kg) and midazolam (5 mg/kg), resulting in deep anesthesia over a period of 2–3 h. Local anesthesia was implemented just before surgery by means of a 10% solution of lidocaine. As prophylaxis they received a single subcutaneous injection of metilprednisolone (10 mg/kg) and dexamethasone (0.1 mg/kg) delivered at the end of the surgical procedure and daily doses of intramuscular injection of enrofloxacin (5 mg/kg) over a period of 7 days. Analgesia was achieved with a single subcutaneous injection of carprofen (4 mg/kg–0.08 ml/Kg) delivered at the end of the surgical procedure and repeated 24 and 48 h post-surgery. After surgery, animals were kept under constant monitoring in single cages with ad libitum access to food and water.
Stereotaxic coordinates for the putamen, the caudate and GPi nuclei were taken from the atlas by Lanciego and Vázquez (). During surgery, target selection was assisted by ventriculography. Selected coordinates: caudate nucleus 1 mm rostral to the anterior commissure, 4.5 mm lateral to the midline and 5 mm dorsal to the intercommisural plane; putamen nucleus 1 mm caudal to the anterior commissure, 11 mm lateral to the midline and 2 mm ventral to the intercommissural plane. GPi 4.5 mm caudal to the anterior commissure, 8 mm lateral to the midline and 1.5 mm ventral to the intercommissural plane.
Two monkeys received a single pressure-injection of 5 µl of unconjugated cholera toxin subunit B (CTB, List Biological Laboratories, Campbell, CA) through a Hamilton syringe (5 mg/ml in 0.01 M phosphate buffer (PB), pH 7.5) in the dorsolateral postcommissural putamen. An additional single pressure-injection of 0.5 µl of Fluorogold (FG) through a Hamilton syringe (10% in 0.01 M PB (pH 7.5) was made in the head of the caudate nucleus. Both injections were made in the same monkey and in the same side of the brain. Two additional monkeys received a single pressure-injection of 5 µl of CTB through a Hamilton syringe (5 mg/ml in 0.01 M PB, pH 7.5) in the internal division of the globus pallidus. Tracer delivery was accomplished in pulses of 1or 0.1 µl every 2 min. Once completed, the microsyringes were left in place for 15 min before withdrawal to minimize tracer uptake through the injection tract.
Two weeks post-surgery, animals were anesthetized with an overdose of 10% chloral hydrate and perfused transcardially. The perfusates consisted of a saline Ringer solution followed by 3,000 ml of a fixative solution containing 4% paraformaldehyde and 0.1% glutaraldehyde in 0.125 M PB, pH 7.4. Perfusion was continued with 1,000 ml of a cryoprotectant solution containing 10% glycerin and 2% dimethylsulphoxide (DMSO) in 0.125 M PB, pH 7.4. Once perfusion was completed, the skull was opened, the brain removed and stored for 48 h in a cryoprotectant solution containing 20% of glycerin and 2% DMSO in 0.125 M PB, pH 7.4. Finally, frozen serial sagittal or coronal sections (40 µm-thick) were obtained on a sliding microtome and collected in 0.125 M PB cryoprotectant solution containing 20% of glycerin and 2% DMSO in 0.125 M PB, pH 7.4, as 10 series of adjacent sections.
Detection of transported CTB and fluorogold
Immunohistochemical detection of transported CTB and FG was carried out on coronal sections. Sections were incubated with a primary antibody against CTB raised in goat (1:2000; List Biologicals, INC, 703) and rabbit antibody Anti-Fluorescent Gold (1:2000; Chemicon, AB153), diluted in a solution containing 5% of normal donkey serum (NDS) (Jackson inmunoresearch Laboratories, 017-000-121), 5% normal swine serum (Jackson immunoresearch Laboratories, 014-00-121), 0.04% triton X-100 in phosphate buffer (PBS) pH 7.4 overnight. After rinsing in PBS, sections were incubated for 2 h in a solution containing 5% of NSwS, 5% NDS, swine anti-rabbit IgG (1:50, Dako, Z0196) and donkey anti-goat (Jackson Immunoresearch, 705-065-147) diluted in PBS for 90 min; after washes sections were incubated in a solution containing 5% NDS and Goat PAP (1:600 Sigma, P1901) and afterwards washed in PBS and visualized in brown with DAB (Sigma, D5637). Section were washed in PBS and incubated in a solution containing 5% NSwS and Rabbit PAP (1:50 Dako, Z0113 diluted in PBS and visualized using Vector VIP Peroxidase (HRP) Substrate Kit (Vector laboratories, SK-4600). Sections were mounted on gelatin-coated glass slides, dried at RT and coverslip with Dpex (VWR International).
Detection of transported CTB and FG combined with TH and CB immunofluorescence
The following primary antibodies were used in double inmunofluorescence: (1) a mouse anti-calbindin-D-28K (1:2000, Sigma, C9848); (2) a goat anti- TH (1:50, Santa Cruz, sc-7847); (3) a rabbit anti-Fluorescent Gold Antibody (1:2000, Chemicon, AB153); and (4) a rabbit anti-CTB (1:2000, Genway, 18-272-195906).
In the present study we have used the following secondary antibodies: Alexa Fluor® 633 Donkey Anti-Mouse IgG (1:200, Molecular Probes A 21082); Alexa Fluor® 546 donkey anti-goat IgG (1:200, Molecular Probes A 11056), Alexa Fluor® 488 donkey anti-rabbit IgG (1:200, Molecular Probes A 21206), biotinylated Donkey anti-rabbit IgG (1:600, Jackson Laboratories, 711-066-152) and biotinylated Donkey anti-mouse IgG (1:600, Jackson Laboratories, 715-066-150).
For single and triple immunohistochemistry, free-floating sections were incubated in a blocking solution containing 5% of NDS and 0.04% triton X-100 in PBS pH 7.4 for an hour. After that, sections were incubated overnight at room temperature with the appropriate primary antibody or mix of antibodies, diluted in a solution of 5% NDS, 0.04% triton X-100 in PBS.
For single immunohistochemistry, after rinsing in PBS, sections were sequentially incubated with the appropriate secondary antibody diluted in a solution containing 5% of NDS in PBS for 2 h and afterwards washed in PBS. Finally sections were incubated in a solution of HRP-conjugated streptavidin (1:5000, Sigma, E2886) diluted in PBS for 90 min and visualized in brown with DAB (Sigma, D5637).
For triple immunofluorescence, after rinsing with PBS sections were incubated with the appropriated fluorescent secondary antibodies and diluted in a solution containing 5% NDS in PBS for 2 h.
Finally, sections were rinsed in PBS and mounted on SuperFrost Ultra Plus® slides, dried at RT and coverslip with Dpex (VWR International).
Sections sampled and quantification of TH+/CB+ co-localization
One series of sections from three control and three MPTP-treated macaques were used for quantifying TH+/CB+ co-localization in double-stained material. Briefly, three equally-spaced coronal sections through the mesencephalon (1.5 mm apart from each other) were entirely scanned under the confocal microscope. One section was taken at the level of the exit of the third cranial nerve to properly elucidate the boundaries between the SNc and VTA. Next, two more rostral and caudal coronal sections (1.5 mm rostral and caudal to the exit of the third cranial nerve, respectively) were chosen for counting purposes. The percentages of co-localization were gathered from 2,615 +/− 640 TH+ neurons in control macaques and from 1,112 +/− 145 TH+ neurons in MPTP-treated animals.
Confocal visualization settings
Stained samples (immunofluorescence and PLA) were inspected under a Zeiss 510 Meta confocal laser-scanning microscope (CLSM). To ensure appropriate visualization of the labeled elements and to avoid false positive results, the emission from the argon laser at 488 nm was filtered through a band pass filter of 505–530 nm and color-coded in green. The emission following excitation with the helium laser at 543 nm was filtered through a band pass filter of 560–615 nm and color coded in red. Finally, a long-pass filter of 650 nm was used to visualize the emission from the helium laser at 633 nm and color coded in pale blue.
Results
TH and CB expression in control and MPTP-treated monkeys
All three monkeys intoxicated with MPTP developed a stable parkinsonian syndrome between 5 and 8 months after the initiation of MPTP administration, scoring between 19–23 points in the accumulative Kurlan scale (Kurlan et al., ). The immunohistochemistry for TH confirmed the extension of the nigrostriatal damage induced in the three monkeys treated with MPTP, when compared with the TH stain in the control monkeys (Figure 1).
Figure 1
Overall, the pattern of degeneration in the ventral midbrain and striatum was similar for the three monkeys. As expected, the caudate and putamen of control monkeys showed numerous and intense TH-ir (Figure 1A), whereas MPTP-treated monkeys showed a marked reduction in TH density in both caudate and putamen nuclei (Figure 1I). In control monkeys, TH-ir neurons were easily noticed in the dorsal and ventral tiers of the SNc (Figures 1B–D). MPTP treatment induced a severe loss of dopaminergic neurons, although few TH-ir cells within the dorsal and ventral tiers of the SNc were still visible. (Figures 1J–L). By contrast, only very small differences in TH immunoractivity were observed in the VTA when comparing control and MPTP-treated monkeys (Figures 1C,K).
CB immunohistochemistry in control and MPTP-treated monkeys was carried out using sections adjacent to those stained for TH. The striatum, SNc (rostral, medial and caudal), and VTA showed similar levels of CB-immunoreactivity (CB-ir) in both control and MPTP-treated monkeys (Figure 1).
Double-labeling stains for TH and CB were carried out in the VTA and SNc in control and MPTP-treated monkeys (Figure 2). In control animals, and in keeping with previous studies, the highest percentage of co-localization was found in the VTA, where 58.2% of TH-ir neurons also showed immunoreactivity for CB (Figure 2). At the level of the SNc, 34.7% of TH-ir neurons from the dorsal tier (SNcd, medial and lateral territories) also expressed CB-ir, whereas TH-ir neurons in the ventral tier did not colocalized with CB. As expected, TH-ir neurons located in the ventral tier (SNcv) lacked CB immunoreactivity (Figure 2). MPTP-treated macaques showed a similar percentage of TH/CB colocalization in the VTA (62.1%). Moreover, most of the surviving TH-ir neurons (88.6%) in the SNcd also expressed CB (Figure 2). Similar to what was found in the SNcv for control macaques, TH-ir neurons in the SNcv did not expressed CB in MPTP-treated animals (Figure 2).
Figure 2
Distribution of nigrostriatal-projecting neurons within the SNc as seen with retrograde tracers
Control animals received two injections of the retrograde tracers FG and CTB into the caudate and putamen nuclei, respectively. Tracer leakage through the injection tracts was not observed in any of the injected animals (Figures 3A,B). In all cases, CTB- and FG -labeled neurons were found throughout rostral, medial and caudal territories of the ipsilateral SNc (Figures 3C–E), and in the ipsilateral VTA. Labeled neurons were distributed in clusters across the entire rostrocaudal extent of the SNc. Although both types of projection neurons were intermingled with each other in all clusters, double-labeled neurons were never observed (Figures 3F–K). Few scattered cells labeled with either CTB or FG were also found in the VTA.
Figure 3
Expression of TH and CB in identified nigrostriatal dopaminergic neurons
To elucidate the presence of CB-ir within identified nigrostriatal-projecting midbrain dopaminergic neurons, triple immunofluoresce stains detecting TH, CB and FG or CTB were conducted in control animals (Figures 4, 5). Following the deposit of FG in the caudate nucleus, labeled neurons were found in both the dorsal and ventral tiers of the SNc, as well as in the VTA (Figure 4). All FG immunoreactive neurons (FG-ir) expressed TH. As described above, CB-ir was only found in a subpopulation of TH-ir neurons in the SNcd and in the VTA (Figure 4). However, none of the TH-ir/CB-ir neurons in SNcd and VTA showed FG labeling.
Figure 4
Figure 5
Similar results were obtained following the delivery of CTB in the putamen nucleus. All the observed CTB immunoreactive neurons (CTB-ir) were identified as TH-ir in SNcd, SNcv and VTA territories. Furthermore, all CB-ir neurons were also positive for TH. Similarly to what was observed for nigro-caudate projection neurons, none of the nigro-putaminal projection neuron did express CB (Figure 5). In other words, our tract-tracing data indicated that although the identified nigrostriatal-projecting neurons (innervating wither the caudate or the putamen nucleus) were all TH-ir, all these neurons completely lacked CB immunoreactivity.
Expression of TH and CB in neurons giving rise to nigroextrastriatal projections
Although the data gathered from identified nigrostriatal neurons showed that these neurons did not contain CB, the basal ganglia territories innervated by neurons co-expressing TH and CB remained to be elucidated. Accordingly, two more control primates were injected with CTB in the internal section of the globus pallidus (GPi) to further identify nigroextrastriatal neurons innervating the GPi (Figure 6A). Tracer leakage through the needle tract was not seen in any of the injected animals (Figure 6A).
Figure 6
The simultaneous triple stain for TH, CB and CTB showed that TH and CB co-localized in all the observed CTB-ir neurons. In other words, the observed nigro-pallidal projection neurons in the VTA and SNcd were all CB-ir/TH-ir (Figure 6).
Discussion
CB have been proposed as a resilience factor in the DA neurons of the midbrain; the presence of this calcium binding protein could efficiently buffer Ca+2, therefore reducing vulnerability to mitochondrial toxins, ultimately conferring resistance to the PD-related toxins (Gerfen et al., , ; Yamada et al., 1990; German et al., ; Ito et al., ; Ng et al., ; Damier et al., ; Hurley et al., ; Yuan et al., 2013).
In the present work we have studied the content of CB within identified subpopulations of TH-ir cells located in the VTA and the SNc. Our results showed the presence of CB in TH-ir cells located in the VTA and in the SNcd, whereas CB was absent in the TH-ir cells of the SNcv. We also observed the presence of CB within the few TH-ir surviving cells of the SNcd and in the VTA from MPTP-treated monkeys. These results are in keeping with earlier reports (Gerfen et al., ; Yamada et al., 1990; Lavoie and Parent, ; Varastet et al., 1994; Damier et al., ,). However, after identifying different subpopulations of nigral efferent neurons innervating the caudate, the putamen or the internal division of the globus pallidus, we have found that nigrostriatal-projecting neurons were all CB negative, whereas co-localization of TH and CB was only found in those nigral neurons giving rise to nigroextrastriatal -nigropallidal- projections.
The highest percentage of co-localization of TH and CB was observed in the VTA (58.2%), followed by the SNcd (34.7%), similarly to previous studies in macaques reporting a co-localization rate of 43% in the VTA and 22% in the SNcd (Lavoie and Parent, ). In keeping with Lavoie and Parent (), co-localization of TH and CB was only found in the SNcd, since SNcv neurons lacked CB expression. Those results are also comparable to the TH and CB immunoreactivities observed in the human midbrain, where CB-ir cells were only found in the VTA and SNcd (Damier et al., ).
As expected, the MPTP treatment produced severe dopaminergic depletion in the macaque striatum (German et al., ; Varastet et al., 1994; Jackson-Lewis et al., ; Mazloom and Smith, ; Rico et al., ), together with a gradient of neuronal loss in midbrain dopaminergic nuclei (German et al., ; Lavoie and Parent, ; Rico et al., ). After MPTP administration, TH-ir neurons in the SNcv are almost completely removed, followed by neurons in the SNcd, and to a lesser extent those dopaminergic neurons in the VTA. This heterogeneous pattern of cell loss properly mimicked the one observed in PD patients (German et al., , ; Varastet et al., 1994; Liang et al., ; Oiwa et al., ; Fitzpatrick et al., ). Comparing control and MPTP-treated macaques, similar percentages of TH/CB co-localization were found in the VTA (58.2 vs. 62.1, respectively), whereas at the level of the SNcd, most of the surviving dopaminergic neurons expressed CB following MPTP treatment (88.6% compared to 34.7% in control animals).
Although these data supported the potential neuroprotective effect of CB against MPTP-induced dopaminergic cell degeneration, data gathered from the retrograde tracing studies conducted here envisioned a different argument by showing that nigrocaudate- and nigroputaminal-projecting TH-ir neurons did not expressed CB in the VTA and in the SNcd nuclei. In other words, TH-ir/CB-ir neurons in VTA and SNcd do not innervate the caudate/putamen. Data provided here showed that nigrostriatal-projecting neurons lacked CB, whereas those expressing CB (the most resistant ones against MPTP) were those neurons innervating the GPi through nigroextrastriatal projections. It is worth noting that TH-ir fibers are still observed in the GPi after chronic MPTP treatment (Parent et al., ; Lavoie and Parent, ; Varastet et al., 1994) and indeed earlier reports already suggested that nigroextrastriatal-projecting dopaminergic neurons are less prone to MPTP-induced degeneration (Schneider et al., ; Parent et al., ; Schneider and Dacko, ; Varastet et al., 1994). Nevertheless, it is worth noting that the CTB retrograde tracer deposits made here were all located in the dorsolateral postcommissural putamen and therefore the potential co-localization of CB and TH in VTA/SNcd neurons innervating striatal territories other than the dorsolateral postcommissural putamen cannot be ruled out. Furthermore, nigroextrastriatal targets other than the GPi nucleus such as the subthalamic nucleus and the external division of the globus pallidus were not investigated in this study.
Concluding remarks
The potential role of the nigroextrastriatal system in PD pathophysiology has long been neglected (Rommelfanger and Wichmann, ) and indeed some studies have suggested that this system plays an important role in the early compensatory changes in PD (Obeso et al., ). Here we have found that midbrain dopaminergic neurons innervating extrastriatal targets were the only ones containing CB. Data reported here sustain the presence of a potential imbalance between the nigrostriatal and nigroextrastriatal systems in advanced diseases states. It seems clear that dopaminergic inputs reaching the GPi nucleus are better preserved that striatal dopaminergic innervation. Compared to the early degeneration of the nigrostriatal system, the nigroextrastriatal system is less prone to degenerate, a phenomenon that merits further research efforts in order to properly elucidate their role both in the normal and diseased basal ganglia.
Statements
Acknowledgments
Supported by grants from Ministerio de Economía y Competitividad (BFU2012-37907, SAF2008-03118-E), Eranet-Neuron, CiberNed (CB06/05/0006), and by the Departamento de Salud, Gobierno de Navarra. Salary for Salvador Sierra is partially supported by a grant from Mutual Médica.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Afonso-OramasD.Cruz-MurosI.Alvarez de la RosaD.AbreuP.GiráldezT.Castro-HernándezJ.et al. (2009). Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson’s disease. Neurobiol. Dis.36, 494–508. 10.1016/j.nbd.2009.09.002
2
Anaya-MartinezV.Martinez-MarcosA.Martinez-FongD.AcevesJ.ErlijD. (2006). Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: implications for abnormal motor behavior. Neuroscience143, 477–486. 10.1016/j.neuroscience.2006.08.033
3
CaudleW. M.RichardsonJ. R.WangM. Z.TaylorT. N.GuillotT. S.McCormackA. L.et al. (2007). Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci.27, 8138–8148. 10.1523/jneurosci.0319-07.2007
4
ChoiW. S.LeeE.LimJ.OhY. J. (2008). Calbindin-D28K prevents drug-induced dopaminergic neuronal death by inhibiting caspase and calpain activity. Biochem. Biophys. Res. Commun.371, 127–131. 10.1016/j.bbrc.2008.04.020
5
CossetteM.LévesqueM.ParentA. (1999). Extrastriatal dopaminergic innervation of human basal ganglia. Neurosci. Res.34, 51–54. 10.1016/s0168-0102(99)00029-2
6
CraggS. J.BaufretonJ.XueY.BolamJ. P.BevanM. D. (2004). Synaptic release of dopamine in the subthalamic nucleus. Eur. J. Neurosci.20, 1788–1802. 10.1111/j.1460-9568.2004.03629.x
7
DamierP.HirschE. C.AgidY.GaybrielA. M. (1999a). The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain122, 1421–1436. 10.1093/brain/122.8.1421
8
DamierP.HirschE. C.AgidY.GaybrielA. M. (1999b). The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain122, 1437–1448. 10.1093/brain/122.8.1437
9
DaveyG. P.BolañosJ. P. (2013). Peroxiredoxin 5 links mitocondrial redox signalling with calcium dynamics: impacto n Parkinson’s disease. J. Neurochem.125, 332–333. 10.1111/jnc.12171
10
FallonJ. H.MooreR. Y. (1978). Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol.180, 545–580. 10.1002/cne.901800310
11
FitzpatrickE.AshkanK.WallaceB. A.BenabidA. L.MitrofanisJ. (2005). Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats. Anat. Embryol. (Berl)210, 101–123. 10.1007/s00429-005-0003-y
12
FrançoisC.SavyC.JanC.TandeD.HirschE. C.YelnikJ. (2000). Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys and in Parkinson’s disease patients. J. Comp. Neurol.425, 121–129. 10.1002/1096-9861(20000911)425:1<121::aid-cne10>3.0.co;2-g
13
GerfenC. R.BaimbridgeK. G.MillerJ. J. (1985). The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. Natl. Acad. Sci. U S A82, 8780–8784. 10.1073/pnas.82.24.8780
14
GerfenC. R.BaimbridgeK. G.ThibaultJ. (1987). The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J. Neurosci.7, 3935–3944.
15
GermanD. C.DubachM.AskariS.SpecialeS. G.BowdenD. M. (1988). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?Neuroscience24, 161–174. 10.1016/0306-4522(88)90320-x
16
GermanD. C.ManaveK.SmithW. K.WoodwardD. J.SaperC. B. (1989). Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization. Ann. Neurol.26, 507–514. 10.1002/ana.410260403
17
GermanD. C.ManayeK. F.SonsallaP. K.BrooksB. A. (1992). Midbrain dopaminergic cell loss in Parkinson’s disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. N Y Acad. Sci.648, 42–62. 10.1111/j.1749-6632.1992.tb24523.x
18
GermanD. C.NelsonE. L.LiangC. L.SpecialeS. G.SintonC. M.SonsallaP. K. (1996). The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration5, 299–312. 10.1006/neur.1996.0041
19
GraceA. A.BunneyB. S. (1983). Intracellular and extracellular electrophysiology of nigral dopaminergic neurons—1. Identification and characterization. Neuroscience10, 301–315. 10.1016/0306-4522(83)90135-5
20
HaberS. N.FudgeJ. L. (1997). The primate substantia nigra and VTA: integrative circuitry and function. Crit. Rev. Neurobiol.11, 323–342. 10.1615/critrevneurobiol.v11.i4.40
21
HarringtonK. A.AugoodS. J.KingsburyA. E.FosterO. J.EmsonP. C. (1996). Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson’s disease. Brain Res. Mol. Brain Res.36, 157–162. 10.1016/0169-328x(95)00278-z
22
HassaniO. K.FrançoisC.YelnikJ.FégerJ. (1997). Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res.749, 88–94. 10.1016/s0006-8993(96)01167-5
23
HedreenJ. C. (1999). Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J. Comp. Neurol.409, 400–410. 10.1002/(sici)1096-9861(19990705)409:3<400::aid-cne5>3.0.co;2-4
24
HurleyM. J.BrandonB.GentlemanS. M.DexterD. T. (2013). Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain136, 2077–2097. 10.1093/brain/awt134
25
ItoH.GotoS.SakamotoS.HiranoA. (1992). Calbindin-D28k in the basal ganglia of patients with parkinsonism. Ann. Neurol.32, 543–550. 10.1002/ana.410320410
26
Jackson-LewisV.JakowecM.BurkeR. E.PrzedborskiS. (1995). Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration4, 257–269. 10.1016/1055-8330(95)90015-2
27
JanC.FrançoisC.TandéD.YelnikJ.TremblayL.AgidY.et al. (2000). Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. Eur. J. Neurosci.12, 4525–4535. 10.1111/j.1460-9568.2000.01351.x
28
KurlanR.KimM. H.GashD. M. (1991). Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov. Disord.6, 111–118. 10.1002/mds.870060205
29
LanciegoJ. L.VázquezA. (2012). The basal ganglia and thalamus of the long-tailed macaque in stereotaxic coordinates. A template atlas based on coronal, sagittal and horizontal brain sections. Brain Struct. Funct.217, 613–666. 10.1007/s00429-011-0370-5
30
LavoieB.ParentA. (1991). Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. Neuroreport2, 601–604. 10.1097/00001756-199110000-00012
31
LavoieB.SmithY.ParentA. (1989). Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry. J. Comp. Neurol.289, 36–52. 10.1002/cne.902890104
32
LiangC. L.SintonC. M.SonsallaP. K.GermanD. C. (1996). Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration5, 313–318. 10.1006/neur.1996.0042
33
LindvallO.BjörklundA. (1979). Dopaminergic innervation of the globus pallidus by collaterals from the nigrostriatal pathway. Brain Res.172, 169–173. 10.1016/0006-8993(79)90907-7
34
LiuY.PeterD.RoghaniA.SchuldinerS.PrivéG. G.EisenbergD.et al. (1992). A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell70, 539–551. 10.1016/0092-8674(92)90425-c
35
LuL.NeffF.FischerD. A.HenzeC.HirschE. C.OertelW. H.et al. (2006). Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson’s disease: a post-mortem study in human control subjects. Neurobiol. Dis.23, 409–421. 10.1016/j.nbd.2006.04.002
36
MazloomM.SmithY. (2006). Synaptic microcircuitry of tyrosine hydroxylase-containing neurons and terminals in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Comp. Neurol.495, 453–469. 10.1002/cne.20894
37
MillerG. W.EricksonJ. D.PerezJ. T.PenlandS. N.MashD. C.RyeD. B.et al. (1999). Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson’s disease. Exp. Neurol.156, 138–148. 10.1006/exnr.1998.7008
38
NgM. C.IacopinoA. M.QuinteroE. M.MarchesF.SonsallaP. K.LiangC. L.et al. (1996). The neurotoxin MPTP increases calbindin-D28k levels in mouse midbrain dopaminergic neurons. Brain Res. Mol. Brain Res.36, 329–336. 10.1016/0169-328x(95)00266-u
39
ObesoJ. A.Rodriguez-OrozM. C.LanciegoJ. L.Rodriguez DiazM. (2004). How does Parkinson’s disease begin? The role of compensatory mechanisms. Trends Neurosci.27, 125–127. 10.1016/j.tins.2003.12.006
40
OiwaY.EberlingJ. L.NagyD.PivirottoP.EmborgM. E.BankiewiczK. S. (2003). Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front. Biosci.8, 155–166. 10.2741/1104
41
ParentA.LavoieB.SmithY.BédardP. (1990). The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys. Adv. Neurol.53, 111–116.
42
ReisnerP. D.ChristakosS.VanamanT. C. (1992). In vitro enzyme activation with calbindin-D28k, the vitamin D-dependent 28 kDa calcium binding protein. FEBS Lett.297, 127–131. 10.1016/0014-5793(92)80342-e
43
RicoA. J.Barroso-ChineaP.Conte-PeralesL.RodaE.Gómez-BautistaV.GendiveM.et al. (2010). A direct projection from the subthalamic nucleus to the ventral thalamus in monkeys. Neurobiol. Dis.39, 381–392. 10.1016/j.nbd.2010.05.004
44
RommelfangerK. S.WichmannT. (2010). Extrastriatal dopaminergic circuits of the Basal Ganglia. Front. Neuroanat.4:139. 10.3389/fnana.2010.00139
45
SchapiraA. H.CooperJ. M.DexterD.ClarkJ. B.JennerP.MarsdenC. D.et al. (1990). Mitochondrial complex I deficiency in Parkinson’s disease. J. Neurochem.54, 823–827. 10.1111/j.1471-4159.1990.tb02325.x
46
SchneiderJ. S.DackoS. (1991). Relative sparing of the dopaminergic innervation of the globus pallidus in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. Brain Res.556, 292–296. 10.1016/0006-8993(91)90318-p
47
SchneiderJ. S.YuwilerA.MarkhamC. H. (1987). Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res.411, 144–150. 10.1016/0006-8993(87)90691-3
48
SelvarajS.SunY.WattJ. A.WangS.LeiS.BirnbaumerL.et al. (2012). Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J. Clin. Invest.122, 1354–1367. 10.1172/JCI61332
49
SelvarajS.WattJ. A.SinghB. B. (2009). TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP(+). Cell Calcium46, 209–218. 10.1016/j.ceca.2009.07.008
50
SmidtM. P.BurbachJ. P. (2007). How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci.8, 21–32. 10.1038/nrn2039
51
SmithY.KievalJ. Z. (2000). Anatomy of the dopamine system in the basal ganglia. Trends Neurosci.23, S28–S33. 10.1016/s1471-1931(00)00023-9
52
SmithY.LavoieB.DumasJ.ParentA. (1989). Evidence for a distinct nigropallidal dopaminergic projection in the squirrel monkey. Brain Res.482, 381–386. 10.1016/0006-8993(89)91205-5
53
SmitsS. M.BurbachJ. P.SmidtM. P. (2006). Developmental origin and fate of meso-diencephalic dopamine neurons. Prog. Neurobiol.78, 1–16. 10.1016/j.pneurobio.2005.12.003
54
SurmeierD. J.GuzmanJ. N.Sanchez-PadillaJ.SchumackerP. T. (2011). The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson’s disease. Neuroscience198, 221–231. 10.1016/j.neuroscience.2011.08.045
55
VarastetM.RicheD.MaziereM.HantrayeP. (1994). Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson’s disease. Neuroscience63, 47–56. 10.1016/0306-4522(94)90006-x
56
WilsonC. J.CallawayJ. C. (2000). Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J. Neurophysiol.83, 3084–3100.
57
YamadaT.McGeerP. L.BaimbridgeK. G.McGeerE. G. (1990). Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res.526, 303–307. 10.1016/0006-8993(90)91236-a
58
YuanH. H.ChenR. J.ZhuY. H.PengC. L.ZhuX. R. (2013). The neuroprotective effect of overexpression of calbindin-D(28k) in an animal model of Parkinson’s disease. Mol. Neurobiol.47, 117–122. 10.1007/s12035-012-8332-3
Summary
Keywords
calbindin, Parkinson’s disease, nigroextrastriatal pathway, neuronal tracers, neuroprotection, MPTP
Citation
Dopeso-Reyes IG, Rico AJ, Roda E, Sierra S, Pignataro D, Lanz M, Sucunza D, Chang-Azancot L and Lanciego JL (2014) Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques. Front. Neuroanat. 8:146. doi: 10.3389/fnana.2014.00146
Received
28 October 2014
Accepted
14 November 2014
Published
03 December 2014
Volume
8 - 2014
Edited by
Javier Blesa, Columbia University, USA
Reviewed by
Henry J. Waldvogel, University of Auckland, New Zealand; Juan Mena-Segovia, University of Oxford, UK
Copyright
© 2014 Dopeso-Reyes, Rico, Roda, Sierra, Pignataro, Lanz, Sucunza, Chang-Azancot and Lanciego.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jose L. Lanciego, Center for Applied Medical Research (CIMA), University of Navarra Medical College, Pio XII Avenue 55, Pamplona 31008, Spain e-mail: jlanciego@unav.es
This article was submitted to the journal Frontiers in Neuroanatomy.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.